Brown Brothers Harriman & CO Ionis Pharmaceuticals Inc Transaction History

Brown Brothers Harriman & CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $6,708 - $8,109	-200 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$34.54 - $47.25 $74,261 - $101,587	-2,150 Reduced 91.49%	200 $8,000
Q1 2021 May 13, 2021	BUY	$42.51 - $63.78 $91,396 - $137,127	2,150 Added 1075.0%	2,350 $106,000
Q4 2020 Feb 16, 2021	BUY	$45.3 - $60.27 $9,060 - $12,054	200 New	200 $11,000
Q2 2020 Aug 13, 2020	SELL	$46.85 - $61.05 $16,866 - $21,978	-360 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$41.6 - $63.4 $7,654 - $11,665	-184 Reduced 33.82%	360 $17,000
Q4 2019 Feb 14, 2020	SELL	$53.85 - $65.27 $323 - $391	-6 Reduced 1.09%	544 $33,000
Q3 2019 Nov 14, 2019	BUY	$59.06 - $72.15 $10,571 - $12,914	179 Added 48.25%	550 $33,000
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $4,097 - $5,685	66 Added 21.64%	371 $24,000
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $6,509 - $9,983	123 Added 67.58%	305 $25,000
Q1 2018 May 14, 2018	SELL	$44.08 - $55.05 $4,187 - $5,229	-95 Reduced 34.3%	182 $8,000
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $4,778 - $6,117	95 Added 52.2%	277 $14,000
Q2 2017 Aug 14, 2017	BUY	N/A	182	182 $9,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

Stay updated on Brown Brothers Harriman & CO with notifications on news.